What is HC Wainwright’s Forecast for InflaRx Q1 Earnings?

InflaRx N.V. (NASDAQ:IFRX) – HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for InflaRx in a research report issued on Thursday, March 19th. HC Wainwright analyst M. Keller expects that the company will post earnings per share of ($0.14) for the quarter. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for InflaRx’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for InflaRx’s Q2 2026 earnings at ($0.13) EPS.

Several other equities analysts also recently commented on the stock. Raymond James Financial reiterated an “outperform” rating on shares of InflaRx in a report on Wednesday, December 31st. Guggenheim cut their target price on shares of InflaRx from $22.00 to $14.00 and set a “buy” rating for the company in a research note on Friday. Leerink Partners reaffirmed a “market perform” rating and set a $2.00 target price (down from $5.00) on shares of InflaRx in a report on Wednesday, December 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research note on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $6.17.

InflaRx Price Performance

Shares of InflaRx stock opened at $0.94 on Friday. The business has a fifty day simple moving average of $0.93 and a two-hundred day simple moving average of $1.15. InflaRx has a 1 year low of $0.71 and a 1 year high of $1.94. The company has a market capitalization of $63.69 million, a price-to-earnings ratio of -1.24 and a beta of 1.48.

InflaRx (NASDAQ:IFRX) last posted its earnings results on Thursday, March 19th. The company reported ($0.17) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.17). The business had revenue of ($0.04) million for the quarter, compared to analyst estimates of $0.03 million.

Institutional Investors Weigh In On InflaRx

Institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC increased its position in InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after acquiring an additional 7,616 shares during the period. Woodline Partners LP bought a new stake in InflaRx in the 1st quarter valued at about $766,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in InflaRx by 158.3% in the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock valued at $118,000 after purchasing an additional 91,927 shares during the period. Adage Capital Partners GP L.L.C. acquired a new position in shares of InflaRx during the 2nd quarter worth approximately $262,000. Finally, Squarepoint Ops LLC increased its holdings in shares of InflaRx by 29.1% during the third quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock worth $253,000 after purchasing an additional 42,489 shares during the period. Institutional investors own 42.39% of the company’s stock.

InflaRx News Roundup

Here are the key news stories impacting InflaRx this week:

• Positive Sentiment: Company highlights promising Phase 2a izicopan data, progress toward Phase 2b readiness in hidradenitis suppurativa (HS), plans for PK bridging in China, active collaborator discussions, and a spring Capital Markets Day to outline the development path—these clinical and strategic updates are the main near‑term catalysts. InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
• Positive Sentiment: Guggenheim maintained a Buy rating while lowering its price target from $22 to $14 — the cut reduces upside vs prior expectations but the firm still signals conviction in the story, which can support the stock. Guggenheim price target note (Benzinga)
• Positive Sentiment: HC Wainwright continues to carry a Buy rating with a $6 target and published near‑term EPS estimates (Q1 2026: -$0.14; Q2 2026: -$0.13), providing analyst support and a clear set of expectations for upcoming quarters. HC Wainwright estimates (MarketBeat)
• Neutral Sentiment: InflaRx reported Q4 EPS of ($0.17), which met consensus, reducing near‑term headline risk from the print itself. Press Release
• Neutral Sentiment: Market coverage and public filings (Business Insider / GlobeNewswire) provide a fuller corporate update on milestones and timelines; these items clarify strategy but do not immediately alter cash or clinical risk. InflaRx full‑year results (Business Insider)
• Negative Sentiment: Revenue remains negligible and the company reported revenue below estimates; InflaRx is still loss‑making with consensus full‑year EPS around -$1.04, underlining ongoing financing and execution risk. Zacks: Q4 loss, revenue miss
• Negative Sentiment: Cash, cash equivalents and marketable securities totaled €46.2M at 12/31/25, which the company says funds operations to mid‑2027 — this finite runway implies potential dilution or financing needs if clinical programs extend or expand. InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.